Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) and KALA BIO (NASDAQ:KALA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Profitability
This table compares Elicio Therapeutics and KALA BIO’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elicio Therapeutics | N/A | -2,748.16% | -151.12% |
| KALA BIO | N/A | -12,971.16% | -83.56% |
Analyst Ratings
This is a breakdown of current ratings for Elicio Therapeutics and KALA BIO, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elicio Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
| KALA BIO | 1 | 4 | 1 | 0 | 2.00 |
Institutional and Insider Ownership
35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Elicio Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.23, meaning that its share price is 323% less volatile than the S&P 500.
Valuation & Earnings
This table compares Elicio Therapeutics and KALA BIO”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elicio Therapeutics | N/A | N/A | -$39.57 million | ($2.40) | -3.99 |
| KALA BIO | N/A | N/A | -$26.98 million | ($96.14) | -0.03 |
Elicio Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.
Summary
Elicio Therapeutics beats KALA BIO on 8 of the 12 factors compared between the two stocks.
About Elicio Therapeutics
Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.
About KALA BIO
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
